reported a very high
(78%) persistence of BZD withdrawal in the CRM group.
In that study, however, study participants received open
label CRM for up to 6 months, while our participants
received CRM only during the 1 month withdrawal
period. This longer CRM use may partly explain the difference
in outcomes. Comparisons with previously published
RCTs [24, 25, 33] must be made with caution due
to subtle but meaningful methodological differences in
design, length of melatonin treatment, use of melatonin
during follow-up and measures reported.